Biosion, Inc.

biosion is a biotech company focusing on the discovery and preclinical development of innovative biologicals for unmet medical needs. leveraging its proprietary h³ (high-throughput high-content high-efficiency) antibody platform and synab™ technology, biosion is committed to develop antibody drug candidates with optimal specificity and mechanistic drug properties. the discovery and early development of superior lead candidates with desired properties is a crucial step in all antibody drug programs, and as such, it is the cornerstone of successful antibody drug development. to overcome this limiting step in innovative antibody drug discovery, the biosion team has established multiple advanced technology platforms to support their "synnovation 100 program". the goal of the synnovation 100 program is to develop first-in-class or best-in-class antibody drug candidates to 100 critically reviewed drug targets. the synnovation 100 drug targets include both novel drug targets as well as newly